Company Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis.
Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations.
The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2011 |
| IPO Date | May 7, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Jennifer Good |
Contact Details
Address: 195 Church Street, 16th Floor New Haven, Connecticut 06510 United States | |
| Phone | 203 304 2499 |
| Website | trevitherapeutics.com |
Stock Details
| Ticker Symbol | TRVI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001563880 |
| CUSIP Number | 89532M101 |
| ISIN Number | US89532M1018 |
| Employer ID | 45-0834299 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jennifer L. Good | Co-Founder, Chief Executive Officer, President and Director |
| Lisa Delfini | Chief Financial Officer |
| Dr. James V. Cassella Ph.D. | Chief Development Officer |
| Dr. Thomas R. Sciascia M.D. | Co-Founder and Chief Scientific Officer |
| Christopher Galletta | Controller and Chief Accounting Officer |
| Katie McManus | Communications Manager |
| Farrell Simon Pharm.D. | Chief Commercial Officer |
| Katherine Takaki Ph.D. | Senior Vice President of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 424B5 | Filing |
| Jun 2, 2025 | 424B5 | Filing |
| Jun 2, 2025 | 8-K | Current Report |
| Jun 2, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |